Eli Lilly’s weight loss drug, tirzepatide, showed substantial potential in a large Phase 3 study, the results of which were reported on April 28th. If tirzepatide gets approved, it could become a blockbuster. But, this isn’t a sure thing. It will have to overcome pricing and reimbursement obstacles.
Subscribe to:
Post Comments (Atom)
< + > A Demo of Truven Health Insights Turning Data Into Actionable Insights
Renee Wiczorek, Lead Product Manager at Truven by Merative , wants healthcare institutions to ask the deep questions about the trends they’...
No comments:
Post a Comment